Optimi Health produces psilocybin capsules for Phase II MDD study
Optimi Health has completed the production and quality release of a batch of 5mg psilocybin capsules for a Health Canada-authorised Phase II MDD trial and commercial supply to Australia.
The post Optimi Health produces psilocybin capsules for Phase II MDD study appeared first on Clinical Trials Arena .